BBIO logo

BRIDGEBIO PHARMA INC

BBIONASDAQ
🏆 #511 by market capEarnings Nov 4US Equity
$83.70▼ $0.96 (−1.15%)
🌙 After hours$83.98▲ 0.33%Regular close · extended-hours price shown
1h—
24h▼ 1.1%
7d—
14d—
30d—
1y—
🏦Market Cap
$16.39B
Mid Cap
📈Revenue Growth (YoY)
+355.2%
High Growth
📊Gross Margin
95.1%
High
💵FCF Margin
—
⚖️P/S Ratio
28.7x
Expensive
Otter Score
51
Weak
📊

Analyst Ratings

Price
$83.70
Total
26
Raised
0
Lowered
2
Avg PT
$103.75
H / L
$130 / $83
InstitutionActionRatingDate
Citigroup
ReiteratedNeutral2026-07-16
HC Wainwright & Co.
ReiteratedBuy2026-07-13
Mizuho
ReiteratedOutperform2026-06-16
Morgan Stanley
ReiteratedOverweight2026-05-28
Raymond James
DowngradedOutperform → Market Perform2026-05-26
Evercore ISI Group
ReiteratedOutperform2026-05-08
Truist Securities
ReiteratedBuy2026-04-29
JP Morgan
ReiteratedOverweight2026-03-10
Oppenheimer
ReiteratedOutperform2026-02-25
Wells Fargo
ReiteratedOverweight2026-02-13
Leerink Partners
ReiteratedOutperform2025-12-15
Goldman Sachs
ReiteratedBuy2025-10-31
Piper Sandler
ReiteratedOverweight2025-10-30
TD Cowen
ReiteratedBuy2025-10-30
Cantor Fitzgerald
ReiteratedOverweight2025-10-30
UBS
ReiteratedBuy2025-09-12
Scotiabank
ReiteratedSector Outperform2025-08-06
B of A Securities
ReiteratedBuy2025-06-25
Jefferies
DowngradedBuy → Hold2023-07-18
SVB Securities
ReiteratedOutperform2023-04-13
Cowen & Co.
ReiteratedOutperform2023-02-06
SVB Leerink
ReiteratedOutperform2023-01-23
BTIG
ReiteratedBuy2020-05-19
H.C. Wainwright
ReiteratedBuy2020-04-13
Piper Jaffray
ReiteratedOverweight2019-07-22
BMO Capital
ReiteratedOutperform2019-07-22
One row per institution, most recent rating